asparaginase 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
enzymes	5070	9015-68-3

Description:

Molecule	Description
Synonyms: asparaginase elspar	A hydrolase enzyme that converts L-asparagine and water to L-aspartate and NH3. EC 3.5.1.1. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

asparaginase
elspar

A hydrolase enzyme that converts L-asparagine and water to L-aspartate and NH3. EC 3.5.1.1.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Feb. 1, 1994	FDA	MERCK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	386.64	41.32	179	4162	118270	63366411
Venoocclusive liver disease	289.72	41.32	67	4274	4768	63479913
Lennox-Gastaut syndrome	191.15	41.32	30	4311	247	63484434
Osteonecrosis	167.55	41.32	63	4278	24467	63460214
Posterior reversible encephalopathy syndrome	165.28	41.32	57	4284	17288	63467393
Temporal lobe epilepsy	158.54	41.32	27	4314	384	63484297
Haematotoxicity	155.74	41.32	47	4294	9329	63475352
Acute lymphocytic leukaemia recurrent	133.49	41.32	31	4310	2238	63482443
Pneumatosis intestinalis	126.36	41.32	30	4311	2383	63482298
Neutropenia	112.51	41.32	94	4247	174911	63309770
Neurotoxicity	106.46	41.32	41	4300	16949	63467732
Human bocavirus infection	104.79	41.32	19	4322	394	63484287
Secondary immunodeficiency	98.04	41.32	22	4319	1361	63483320
Drug interaction	94.45	41.32	96	4245	229035	63255646
Bone marrow failure	91.07	41.32	43	4298	29247	63455434
Philadelphia chromosome positive	85.77	41.32	16	4325	390	63484291
Enterobacter infection	82.66	41.32	21	4320	2206	63482475
Mucormycosis	77.37	41.32	21	4320	2850	63481831
Drug resistance	75.39	41.32	35	4306	22898	63461783
Partial seizures	74.76	41.32	24	4317	5818	63478863
Gastroenteritis norovirus	69.42	41.32	18	4323	2050	63482631
Human herpesvirus 6 infection	67.56	41.32	19	4322	2938	63481743
Herpes simplex	66.58	41.32	24	4317	8247	63476434
Therapeutic response delayed	66.31	41.32	14	4327	650	63484031
Venous thrombosis	66.28	41.32	21	4320	4881	63479800
Rhinovirus infection	59.57	41.32	19	4322	4510	63480171
T-cell lymphoma refractory	59.40	41.32	9	4332	57	63484624
Clostridium difficile colitis	57.24	41.32	28	4313	20541	63464140
Neuropathy peripheral	56.76	41.32	53	4288	113614	63371067
Cerebral venous sinus thrombosis	55.84	41.32	15	4326	1957	63482724
Enteritis	51.89	41.32	20	4321	8266	63476415
Multiple organ dysfunction syndrome	50.44	41.32	37	4304	56715	63427966
Second primary malignancy	49.10	41.32	19	4322	7934	63476747
Sepsis	48.62	41.32	56	4285	153067	63331614
Aplasia	48.42	41.32	16	4325	4243	63480438
Ileus paralytic	47.38	41.32	16	4325	4535	63480146
Pleuroparenchymal fibroelastosis	47.35	41.32	8	4333	108	63484573
Hepatotoxicity	44.32	41.32	29	4312	37012	63447669
Febrile bone marrow aplasia	43.45	41.32	17	4324	7308	63477373
Cerebral venous thrombosis	41.42	41.32	12	4329	2062	63482619

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	298.60	30.56	229	6405	136620	34813677
Posterior reversible encephalopathy syndrome	214.54	30.56	78	6556	9876	34940421
Haematotoxicity	172.04	30.56	63	6571	8131	34942166
Venoocclusive liver disease	162.64	30.56	60	6574	7906	34942391
Neutropenia	161.08	30.56	172	6462	156606	34793691
Multiple-drug resistance	154.96	30.56	52	6582	5187	34945110
Osteonecrosis	145.09	30.56	66	6568	14824	34935473
Bone marrow failure	90.99	30.56	61	6573	29192	34921105
Mucosal inflammation	77.94	30.56	62	6572	38560	34911737
Acute lymphocytic leukaemia recurrent	77.43	30.56	27	6607	3017	34947280
Multiple organ dysfunction syndrome	73.04	30.56	81	6553	76485	34873812
Septic shock	70.25	30.56	77	6557	71757	34878540
Mucormycosis	69.62	30.56	30	6604	5912	34944385
Cerebral venous thrombosis	69.19	30.56	18	6616	736	34949561
Stomatitis	68.66	30.56	60	6574	42454	34907843
Venoocclusive disease	59.97	30.56	22	6612	2845	34947452
Myelopathy	55.35	30.56	20	6614	2477	34947820
Glioma	54.99	30.56	13	6621	356	34949941
Minimal residual disease	52.81	30.56	13	6621	424	34949873
Haemophagocytic lymphohistiocytosis	52.60	30.56	32	6602	12941	34937356
Aspiration bone marrow abnormal	49.34	30.56	10	6624	130	34950167
Glioblastoma multiforme	46.05	30.56	13	6621	725	34949572
Pancreatitis acute	45.97	30.56	40	6594	28101	34922196
Cerebral venous sinus thrombosis	45.25	30.56	12	6622	529	34949768
Candida endophthalmitis	44.77	30.56	9	6625	112	34950185
Fatigue	43.12	30.56	9	6625	370644	34579653
Large intestine infection	40.67	30.56	14	6620	1504	34948793
Aspergillus infection	39.14	30.56	26	6608	12228	34938069
Drug clearance decreased	38.20	30.56	14	6620	1804	34948493
Pancytopenia	37.77	30.56	66	6568	95091	34855206
Hepatocellular injury	37.14	30.56	32	6602	22179	34928118
Brain sarcoma	37.11	30.56	6	6628	18	34950279
Hepatic calcification	35.33	30.56	9	6625	338	34949959
Adrenomegaly	34.78	30.56	9	6625	360	34949937
Metamyelocyte count increased	34.38	30.56	9	6625	377	34949920
Neurotoxicity	34.35	30.56	28	6606	17982	34932315
Sepsis	33.95	30.56	88	6546	166473	34783824
Fungal infection	33.00	30.56	26	6608	15909	34934388
Encephalopathy	32.98	30.56	37	6597	35282	34915015
Costal cartilage fracture	32.95	30.56	8	6626	246	34950051
Blast cells present	32.02	30.56	9	6625	494	34949803
Pyrexia	31.83	30.56	136	6498	332877	34617420
Cerebellar tumour	30.78	30.56	6	6628	63	34950234

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	612.26	29.72	395	11378	230604	79502011
Secondary immunodeficiency	403.41	29.72	94	11679	3140	79729475
Posterior reversible encephalopathy syndrome	348.79	29.72	135	11638	26146	79706469
Haematotoxicity	307.04	29.72	107	11666	15412	79717203
Bacterial infection	250.23	29.72	112	11661	31168	79701447
Osteonecrosis	241.29	29.72	109	11664	30986	79701629
Neutropenia	239.25	29.72	251	11522	287459	79445156
Mycobacterium chelonae infection	221.69	29.72	55	11718	2401	79730214
Acute lymphocytic leukaemia recurrent	177.34	29.72	53	11720	4671	79727944
Human herpesvirus 6 infection	174.86	29.72	54	11719	5316	79727299
Bone marrow failure	174.16	29.72	103	11670	51004	79681611
Multiple-drug resistance	163.71	29.72	58	11715	8750	79723865
Human bocavirus infection	155.39	29.72	33	11740	712	79731903
Aspergillus infection	154.42	29.72	69	11704	19092	79713523
Pseudomonal sepsis	151.25	29.72	50	11723	6124	79726491
Parainfluenzae virus infection	147.19	29.72	48	11725	5634	79726981
Clostridium difficile colitis	136.67	29.72	75	11698	32208	79700407
Thymus hypoplasia	130.43	29.72	30	11743	943	79731672
Pneumatosis intestinalis	129.90	29.72	45	11728	6352	79726263
Lymphoid tissue hypoplasia	126.41	29.72	29	11744	901	79731714
Viral infection	121.70	29.72	77	11696	42939	79689676
Cerebral venous thrombosis	121.41	29.72	35	11738	2718	79729897
Multiple organ dysfunction syndrome	118.02	29.72	115	11658	120131	79612484
Cystitis bacterial	117.49	29.72	26	11747	684	79731931
Bronchopulmonary aspergillosis	111.83	29.72	58	11715	22236	79710379
Norovirus test positive	108.21	29.72	24	11749	638	79731977
Enterobacter infection	107.96	29.72	36	11737	4526	79728089
Viraemia	102.55	29.72	31	11742	2838	79729777
Abscess bacterial	97.44	29.72	23	11750	811	79731804
Mucormycosis	96.48	29.72	39	11734	8430	79724185
Neurotoxicity	96.47	29.72	60	11713	32458	79700157
Venoocclusive disease	92.19	29.72	32	11741	4541	79728074
Fatigue	91.95	29.72	14	11759	929713	78802902
Rhinovirus infection	91.89	29.72	37	11736	7916	79724699
Myelopathy	91.78	29.72	32	11741	4601	79728014
Cytomegalovirus chorioretinitis	90.17	29.72	33	11740	5457	79727158
Septic shock	87.47	29.72	99	11674	122702	79609913
Cerebral venous sinus thrombosis	87.26	29.72	26	11747	2265	79730350
Coronavirus infection	87.04	29.72	35	11738	7462	79725153
Neuropathy peripheral	85.85	29.72	105	11668	141200	79591415
Mucosal inflammation	83.08	29.72	77	11696	75503	79657112
Hepatotoxicity	82.39	29.72	65	11708	51287	79681328
Diffuse alveolar damage	79.59	29.72	27	11746	3577	79729038
Lennox-Gastaut syndrome	76.93	29.72	15	11758	207	79732408
Cytomegalovirus viraemia	74.94	29.72	37	11736	12784	79719831
Sepsis	72.61	29.72	137	11636	269291	79463324
Glioma	71.86	29.72	17	11756	605	79732010
Oesophageal candidiasis	70.44	29.72	32	11741	9186	79723429
Pancytopenia	68.34	29.72	102	11671	165643	79566972
Fungal infection	67.30	29.72	53	11720	41695	79690920
Pancreatitis acute	65.35	29.72	56	11717	49548	79683067
Philadelphia chromosome positive	65.02	29.72	16	11757	674	79731941
Pain	62.19	29.72	14	11759	703788	79028827
Leukaemia recurrent	62.11	29.72	21	11752	2753	79729862
Enteritis	62.02	29.72	34	11739	14549	79718066
Neoplasm recurrence	60.68	29.72	23	11750	4191	79728424
Glioblastoma multiforme	60.39	29.72	17	11756	1211	79731404
Second primary malignancy	57.04	29.72	32	11741	14318	79718297
Intracardiac thrombus	56.69	29.72	22	11751	4271	79728344
Drug resistance	56.30	29.72	48	11725	42165	79690450
Aplasia	56.16	29.72	26	11747	7794	79724821
Temporal lobe epilepsy	55.78	29.72	13	11760	433	79732182
Malaise	54.16	29.72	5	11768	489864	79242751
Disseminated aspergillosis	52.82	29.72	15	11758	1103	79731512
T-cell lymphoma refractory	52.47	29.72	9	11764	57	79732558
Hypertriglyceridaemia	52.24	29.72	29	11744	12711	79719904
Febrile bone marrow aplasia	51.65	29.72	29	11744	12991	79719624
Hyperammonaemia	50.33	29.72	27	11746	11066	79721549
Hepatocellular injury	49.42	29.72	47	11726	47546	79685069
Encephalopathy	49.07	29.72	55	11718	67342	79665273
Thrombocytopenia	48.29	29.72	115	11658	265144	79467471
Therapeutic response delayed	48.05	29.72	14	11759	1128	79731487
Herpes simplex	47.96	29.72	27	11746	12160	79720455
Haemophagocytic lymphohistiocytosis	47.02	29.72	33	11740	21804	79710811
Encephalitis	45.70	29.72	28	11745	14732	79717883
Brain sarcoma	45.30	29.72	7	11766	20	79732595
Tumour lysis syndrome	44.29	29.72	33	11740	23906	79708709
Candida endophthalmitis	43.66	29.72	9	11764	167	79732448
Dizziness	43.49	29.72	12	11761	526429	79206186
Aplastic anaemia	43.14	29.72	29	11744	17876	79714739
Leukopenia	42.78	29.72	68	11705	116445	79616170
Ileus paralytic	42.49	29.72	23	11750	9597	79723018
Pneumonia fungal	41.86	29.72	24	11749	11186	79721429
Fusarium infection	41.53	29.72	14	11759	1818	79730797
Haemangioma	40.69	29.72	15	11758	2530	79730085
Pleuroparenchymal fibroelastosis	38.88	29.72	8	11765	147	79732468
Dyspnoea	38.52	29.72	42	11731	856983	78875632
Partial seizures	38.36	29.72	21	11752	8957	79723658
Cell death	38.09	29.72	17	11756	4682	79727933
Seizure	37.78	29.72	85	11688	188749	79543866
Blast cells present	37.28	29.72	11	11762	926	79731689
Hepatic calcification	36.95	29.72	9	11764	363	79732252
Enterococcal infection	36.85	29.72	25	11748	15635	79716980
Drug clearance decreased	36.79	29.72	15	11758	3312	79729303
Product use in unapproved indication	36.66	29.72	100	11673	250259	79482356
Stomatitis	36.24	29.72	72	11701	146685	79585930
Adrenomegaly	36.06	29.72	9	11764	402	79732213
Cerebellar tumour	35.74	29.72	7	11766	99	79732516
Nausea	35.69	29.72	54	11719	957142	78775473
Diarrhoea	35.47	29.72	47	11726	880442	78852173
Lymphopenia	35.24	29.72	32	11741	30525	79702090
Costal cartilage fracture	34.49	29.72	8	11765	261	79732354
Arthralgia	34.37	29.72	21	11752	571782	79160833
Large intestine infection	34.06	29.72	14	11759	3155	79729460
Hepatosplenic candidiasis	32.86	29.72	9	11764	579	79732036
Pseudomonas infection	32.52	29.72	26	11747	20877	79711738
Metamyelocyte count increased	32.11	29.72	9	11764	631	79731984
Pyrexia	31.47	29.72	189	11584	678520	79054095
Inappropriate antidiuretic hormone secretion	31.21	29.72	28	11745	26285	79706330
Gastroenteritis norovirus	30.95	29.72	13	11760	3093	79729522
Pancreatitis	30.82	29.72	44	11729	68531	79664084

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01XX02	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Other antineoplastic agents
FDA CS	M0001815	Asparaginase
MeSH PA	D000970	Antineoplastic Agents
FDA EPC	N0000175669	Asparagine-specific Enzyme

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Acute lymphoid leukemia	indication	91857003	DOID:9952

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
G4FQ3CKY5R	UNII
4017974	VANDF
C0003993	UMLSCUI
CHEMBL2108989	ChEMBL_ID
5460875	PUBCHEM_CID
DB00023	DRUGBANK_ID
D001215	MESH_DESCRIPTOR_UI
1156	RXNORM
4222	MMSL
688	MMSL
002673	NDDF
18811003	SNOMEDCT_US
370969007	SNOMEDCT_US
371014004	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Rylaze	HUMAN PRESCRIPTION DRUG LABEL	1	68727-900	INJECTION	20 mg	INTRAMUSCULAR	BLA	25 sections
Rylaze	HUMAN PRESCRIPTION DRUG LABEL	1	68727-900	INJECTION	20 mg	INTRAMUSCULAR	BLA	25 sections